Prediction of Clinical Responses in a Simulated Phase III Trial of Crohn's Patients Administered the Antisense Phosphorothioate Oligonucleotide ISIS 2302: Comparison of Proposed Dosing Regimens-Reference-Cited by-同舟云学术

Prediction of Clinical Responses in a Simulated Phase III Trial of Crohn's Patients Administered the Antisense Phosphorothioate Oligonucleotide ISIS 2302: Comparison of Proposed Dosing Regimens

Published:2003-02 Issue:1 Volume:13 Page:57-66
ISSN:1087-2906
Container-title:Antisense and Nucleic Acid Drug Development
language:en
Short-container-title:Antisense and Nucleic Acid Drug Development

Author:

Yu Rosie Z.¹,Su John Q.¹,Grundy John S.¹,Geary Richard S.¹,Sewell K. Lea¹,Dorr Andrew¹,Levin Arthur A.¹

Affiliation:

1. ISIS Pharmaceuticals, Inc., Carlsbad, California 92008

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology,Genetics

Link

http://www.liebertpub.com/doi/pdf/10.1089/108729003764097340

Reference16 articles.

1. Role of modelling and simulation in Phase I drug development

2. Height-Weight Tables

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a stepwise solvent-gradient SMB process for continuous-mode purification of methoxyethyl nucleoside phosphoramidites to be used as the key building blocks of oligonucleotide drugs;Chemical Engineering Journal;2023-08

2. Activated Eosinophils in Association with Enteric Nerves in Inflammatory Bowel Disease;PLoS ONE;2013-05-22

3. Models for Disease Progression: New Approaches and Uses;Clinical Pharmacology & Therapeutics;2012-05-23

4. A two-step sulfurization for efficient solution-phase synthesis of phosphorothioate oligonucleotides;Tetrahedron Letters;2008-05

5. Encapsulation of Nucleic Acids and Opportunities for Cancer Treatment;Pharmaceutical Research;2007-02-15